BioNTech co-founder Uğur Şahin told BBC One’s The Andrew Marr Show on Sunday: “this winter will be hard and the vaccine will not have a big impact on the infection numbers
Topics
Pfizer | Coronavirus Vaccine
Agencies | Mainz (Germany)
Last Updated at November 16, 2020 00:39 IST
The scientist behind the first potential Covid-19 vaccine to clear interim clinical trials and has been found to be 90 per cent effective said that “if everything continues to go well…we could have a normal winter next year.
BioNTech co-founder UgurSahintold BBC One’s The Andrew Marr Show on Sunday: “this winter will be hard and the vaccine will not have a big impact on the infection numbers. But he said that if everything continues to go well, the goal is to deliver more than 300 million doses of the vaccine before April next year, which could allow us to already start to make an impact.”
He added that “what is absolutely essential is that we get a high vaccination rate before autumn/winter next year … so all the vaccination and immunisation approaches must be accomplished before next autumn — and I’m confident that this will happen because a number of vaccine companies are helping us to increase the supply — so that we could have a normal winter next year.”
Sahin said the scientists would have a better understanding of the vaccine candidate’s impact in slowing transmission “in a few months” following further analysis of the antibody response in trial participants.
BioNTech and Pfizer confirmed last week that they had completed a deal for the European Commission to purchase up to 300 million doses of their coronavirus vaccine. The companies announced their vaccine was found to be 90 percent effective on Monday.
“As a company founded in the heart of Europe, we are looking forward to supplying millions of people upon regulatory approval,” Sahinwrote in a statement.
On Sunday, Sahinalso said that his company didn’t receive any help from the US government’s Operation Warp Speed, as claimed by President Donald Trump.
“We decided from the very beginning to stay independent,” Sahinsaid, “to ensure that … we are able to deliver the vaccine to any place on the planet where it is needed. Therefore, we didn’t get direct support from Operation Warp Speed.”
While Pfizer did not accept direct Operation Warp Speed funding for research, the US government promised to purchase $1.95 billion worth of the vaccine through the Warp Speed program if it’s approved, a key guarantee.
In June, BioNTech secured a €100 million loan from the European Investment Bank to increase manufacturing capacity.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
First Published: Mon, November 16 2020. 00:33 IST
read the full story about Covid-19 crisis: Normal life back likely next winter, says BioNTech CEO
#theheadlines #breakingnews #headlinenews #newstoday #latestnews #aajtak #ndtv #timesofindia #indiannews